Clinical Trial Update: Use of Regorafenib in Recurrent Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating regorafenib in recurrent epithelial ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED